Astellas Pharma Inc. logo

Astellas Pharma Inc. (ALPMF)

Market Closed
8 Jul, 20:00
OTC PINK OTC PINK
$
9. 37
-0.24
-2.5%
$
18.08B Market Cap
- P/E Ratio
0.88% Div Yield
700 Volume
- Eps
$ 9.61
Previous Close
Day Range
9.37 9.37
Year Range
8.4 12.74
Want to track ALPMF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 20 days

Summary

ALPMF closed today lower at $9.37, a decrease of 2.5% from yesterday's close, completing a monthly increase of 0.11% or $0.01. Over the past 12 months, ALPMF stock lost -5.07%.
ALPMF pays dividends to its shareholders, with the most recent payment made on Jun 03, 2025. The next estimated payment will be in 1 month ago on Jun 03, 2025 for a total of $0.2468.
The last earnings report, released on Apr 23, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.97%, based on the last three reports. The next scheduled earnings report is due on Jul 29, 2025.
Astellas Pharma Inc. has completed 1 stock splits, with the recent split occurring on Mar 27, 2014.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

ALPMF Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript

Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript

Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Naoki Okamura - Representative Director, President & Chief Executive Officer Claus Zieler - Chief Commercial Officer & Medical Affairs Officer Tadaaki Taniguchi - Chief Medical Officer Atsushi Kitamura - Chief Financial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Akinori Ueda - Goldman Sachs Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Hiroyuki Matsubara - Nomura Securities Miki Sogi - Sanford C. Bernstein Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - UBS Securities Hiromitsu Ikeda Thank you very much for joining our FY 2024 Financial Results Announcement Meeting by Astellas Pharma Inc. out of your very busy schedule today.

Seekingalpha | 2 months ago
Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward

Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward

Astellas Pharma Inc. has a diverse pipeline with significant growth in oncology, driven by new approvals for drugs like zolbetuximab. Despite recent stock declines, ALPMF's revenue and core profits have grown, supported by strong sales of enzalutamide and faster-than-expected zolbetuximab market penetration. Operational expenses have increased due to amortization and terminated projects, impacting operating profit, but new product launches and approvals indicate potential for future growth.

Seekingalpha | 3 months ago
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript

Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript

Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2024 Earnings Conference Call February 4, 2025 2:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Atsushi Kitamura - Chief Financial Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Akinori Ueda - Goldman Sachs Securities Hiroyuki Matsubara - Nomura Securities Shinichiro Hyogo - Mitsubishi UFJ Trust Bank Miki Sogi - Sanford C. Berstein Fumiyoshi Sakai - UBS Securities Kazuaki Hashiguchi - Daiwa Securities Hiromitsu Ikeda Thank you very much for your attendance on to this Q3 Y-to-D FY '24 Financial Results Announcement Meeting.

Seekingalpha | 5 months ago

Astellas Pharma Inc. Dividends

Astellas Pharma Inc. logo
ALPMF In 8 months
Other
$0.27 Per Share
Astellas Pharma Inc. logo
ALPMF In 2 months
Other
$0.27 Per Share
Astellas Pharma Inc. logo
ALPMF 3 months ago
Paid
Other
$0.25 Per Share
Astellas Pharma Inc. logo
ALPMF 9 months ago
Paid
Other
$0.24 Per Share
Astellas Pharma Inc. logo
ALPMF 9 months ago
Other
$0.26 Per Share

Astellas Pharma Inc. Earnings

31 Jul 2025 (In 3 weeks) Date
10.2
Cons. EPS
-
EPS
29 Jul 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
23 Apr 2025 Date
-
Cons. EPS
-
EPS
2 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
22.6
Cons. EPS
20.06
EPS
Astellas Pharma Inc. logo
ALPMF In 8 months
Other
$0.27 Per Share
Astellas Pharma Inc. logo
ALPMF In 2 months
Other
$0.27 Per Share
Astellas Pharma Inc. logo
ALPMF 3 months ago
Paid
Other
$0.25 Per Share
Astellas Pharma Inc. logo
ALPMF 9 months ago
Paid
Other
$0.24 Per Share
Astellas Pharma Inc. logo
ALPMF 9 months ago
Other
$0.26 Per Share
31 Jul 2025 (In 3 weeks) Date
10.2
Cons. EPS
-
EPS
29 Jul 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
23 Apr 2025 Date
-
Cons. EPS
-
EPS
2 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
22.6
Cons. EPS
20.06
EPS

Astellas Pharma Inc. (ALPMF) FAQ

What is the stock price today?

The current price is $9.37.

On which exchange is it traded?

Astellas Pharma Inc. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is ALPMF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.88%.

What is its market cap?

As of today, the market cap is 18.08B.

When is the next earnings date?

The next earnings report will release on Jul 29, 2025.

Has Astellas Pharma Inc. ever had a stock split?

Astellas Pharma Inc. had 1 splits and the recent split was on Mar 27, 2014.

Astellas Pharma Inc. Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. Naoki Okamura BSc CEO
OTC PINK Exchange
JP3942400007 ISIN
JP Country
14,754 Employees
31 Mar 2026 Last Dividend
27 Mar 2014 Last Split
- IPO Date

Overview

Astellas Pharma Inc. is a distinguished player in the pharmaceutical industry operating not only domestically in Japan but also on an international scale. Founded in 1923 and with its headquarters nestled in Tokyo, Japan, the company has carved a niche for itself through the manufacturing, marketing, importing, and exporting of pharmaceuticals. Astellas's dedication to advancing medical care is proven through its consistent efforts in research and development, which has led to valuable collaborations. Notably, the company has formed a research collaboration with Vivtex Corporation to assess the potential of Vivtex's GI-ORIS screening and formulation technology. This partnership aims to enhance the oral delivery mechanisms of therapeutic candidates offered by Astellas. Additionally, a significant partnership with Roche Diabetes Care Japan Co., Ltd. showcases Astellas's commitment toward advancing diabetes care through the development and commercialization of an integrated diabetes self-management solution, cementing its role as an innovation-driven pharmaceutical powerhouse.

Products and Services

  • XTANDI: A hallmark treatment manufactured by Astellas for prostate cancer. XTANDI stands out for offering patients a fighting chance against this prevalent disease, demonstrating Astellas's commitment to addressing critical oncological conditions.
  • XOSPATA: This innovative medication is designed for patients suffering from relapsed or refractory acute myeloid leukemia harboring a FLT3 mutation, underscoring Astellas’s dedication to targeting specific genetic markers in cancer treatment.
  • PADCEV: Representing a breakthrough in the treatment of metastatic urothelial cancer, PADCEV is indicative of Astellas’s leadership in developing therapies for complex oncological conditions.
  • Evrenzo: A testament to Astellas’s emphasis on addressing chronic conditions, Evrenzo offers relief to patients grappling with anemia associated with chronic kidney disease.
  • Betanis/Myrabetriq/BETMIGA: This product line caters to individuals facing the challenges of an overactive bladder. It underscores Astellas’s focus on improving the quality of life for patients dealing with everyday health conditions.
  • Prograf and Advagraf/Graceptor/ASTAGRAF XL: These immunosuppressants are critical in the management of patients undergoing organ transplants, reflecting Astellas’s contribution to the field of transplant medicine and the importance of facilitating patient recovery and transplant success.

Contact Information

Address: 2-5-1, Nihonbashi-Honcho
Phone: 81 3 3244 3000